China Overtakes Europe as Top Healthcare Investment Pick
A Jefferies survey of senior healthcare executives and investors ranks China second among preferred healthcare investment locations.
Updated on Nov. 16, 2026 in Healthcare

China moved ahead of Europe to become the second most-preferred location for healthcare investment, according to the Jefferies Healthcare Temperature Check, which polled senior healthcare executives and investors. North America was cited as the greatest value opportunity by 73% of respondents.
Why it matters
China's rise follows record levels of biopharma out-licensing activity as global pharmaceutical companies seek access to new drug candidates. The shift reflects a change in where clinical development and deal activity are concentrated.
The Jefferies survey found 47% of respondents chose China as a top investment location, ahead of 27% for Europe excluding the UK. China's share of global commercial clinical trials climbed from 10% to 30% over the past decade, while Europe's fell from 18% to 9%.
The players
Jefferies
Jefferies is a global investment banking and capital markets firm whose annual Healthcare Temperature Check surveys investors and executives on sector sentiment.
The details
Jefferies published the findings as its global conference got underway in London. Respondents also expected corporate-led M&A to dominate healthcare deal-making in 2027, a view held by 58% of executives, up eight points.
Timeline
Past decade: China's share of global commercial clinical trials rose from 10% to 30%.
2026: Turmoil from inflation, rates, pricing and geopolitics featured in the survey.
2027: Corporate-led M&A is expected to dominate healthcare deal-making.
Health Landscape
The findings extend a documented migration of clinical trial activity toward China over the past decade, with its share of global commercial trials tripling while Europe's roughly halved. Investor sentiment now appears to be following where drug development is physically taking place.
Patients and healthcare workers may see the effects indirectly as drug candidates and clinical trials shift between regions. Investors tracking healthcare stocks should note that mid- and small-cap pharma and biotech are expected to perform best over the next 12 months.
The takeaway
Investor attention is following where drugs are actually being tested, so the geography of clinical development is becoming a useful signal for healthcare investment. Geopolitical risk remains the top concern to monitor.
Further reading
Explore more on Healthcare trends and deal activity across global markets.



